Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week
Abstract Background To evaluate the pharmacokinetic of plasma lopinavir (LPV) and ritonavir (RTV) when co-administered with three times weekly (TPW) rifabutin (RBT) at a dose of either 150 or 300 mg in African tuberculosis (TB) and HIV co-infected adult patients. Methods This is a pharmacokinetic st...
Saved in:
Main Authors: | Henri Gautier Ouedraogo (Author), Alberto Matteelli (Author), Giorgia Sulis (Author), Tegwinde Rebeca Compaore (Author), Serge Diagbouga (Author), Simon Tiendrebeogo (Author), Alberto Roggi (Author), Kadari Cisse (Author), Pier Francesco Giorgetti (Author), Paola Villani (Author), Lassana Sangare (Author), Jacques Simpore (Author), Mario Regazzi (Author), Seni Kouanda (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2020-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
by: Ashish Chandwani, et al.
Published: (2008) -
355 Lopinavir/ritonavir treatment in paediatric patients with covid-19
by: P Ip, et al.
Published: (2021) -
Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
by: Wilhelm P. Greffrath, et al.
Published: (2018) -
Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis
by: Bahman Amani, et al.
Published: (2021) -
Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
by: Christiana Smith, et al.
Published: (2016)